ICD   PCS   Disclaimer
PCS-2023 Procedure Codes Overview
PCS-2023 > X > XW > XW0 > XW04
XW0

Anatomical Regions, Introduction

Info:
Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
XW04

Introduction, Central Vein

XW043
Percutaneous
XW0430
Brexanolone
XW04306
Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6
XW04308
Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
XW0432
Nerinitide
XW04326
Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6
XW0433
Durvalumab Antineoplastic
XW04336
Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
XW0435
Narsoplimab Monoclonal Antibody
XW04357
Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW04358
Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
XW0436
Lefamulin Anti-infective
XW04366
Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW04367
Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
XW04368
Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
XW0437
Coagulation Factor Xa, Inactivated
XW04372
Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
XW04377
Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
XW04378
Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
XW0438
Lurbinectedin
XW04387
Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
XW04388
Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
XW0439
Ceftolozane/Tazobactam Anti-infective
XW04396
Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW04398
Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
XW043A
Cefiderocol Anti-infective
XW043A6
Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043A7
Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
XW043B
Cytarabine and Daunorubicin Liposome Antineoplastic
XW043B3
Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
XW043B6
Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043B7
Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW043C
Eculizumab
XW043C6
Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6
XW043C7
Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043D
Atezolizumab Antineoplastic
XW043D6
Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
XW043E
Remdesivir Anti-infective
XW043E5
Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043E6
Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043F
Other New Technology Therapeutic Substance
XW043F3
Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
XW043F5
Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
XW043F6
Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043G
Plazomicin Anti-infective
XW043G4
Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
XW043G5
Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043G6
Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043G7
Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043H
Synthetic Human Angiotensin II
XW043H4
Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4
XW043H5
Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043H6
Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043H7
Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043J
Tisagenlecleucel Immunotherapy
XW043J7
Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043K
Fosfomycin Anti-infective
XW043K5
Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043K7
Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043L
CD24Fc Immunomodulator
XW043L6
Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
XW043L7
Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043M
Brexucabtagene Autoleucel Immunotherapy
XW043M7
Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043N
Meropenem-vaborbactam Anti-infective
XW043N5
Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043N7
Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043Q
Tagraxofusp-erzs Antineoplastic
XW043Q5
Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
XW043S
Iobenguane I-131 Antineoplastic
XW043S5
Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
XW043U
Imipenem-cilastatin-relebactam Anti-infective
XW043U5
Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043W
Caplacizumab
XW043W5
Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5

 

ICD-10-CM-2023 Code Search Engine and PCS-2023 Code Search Engine